Evermore Global Advisors LLC lifted its holdings in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 3.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 3,685,520 shares of the medical research company’s stock after acquiring an additional 130,287 shares during the period. Enzo Biochem makes up approximately 14.6% of Evermore Global Advisors LLC’s investment portfolio, making the stock its 2nd largest holding. Evermore Global Advisors LLC owned 7.92% of Enzo Biochem worth $38,587,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ENZ. CAPROCK Group Inc. purchased a new stake in shares of Enzo Biochem during the third quarter worth about $118,000. Legal & General Group Plc boosted its position in Enzo Biochem by 10.6% in the second quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after buying an additional 1,022 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Enzo Biochem in the second quarter valued at approximately $124,000. KCG Holdings Inc. purchased a new stake in Enzo Biochem in the first quarter valued at approximately $141,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Enzo Biochem in the second quarter valued at approximately $155,000. Institutional investors and hedge funds own 63.99% of the company’s stock.

A number of equities research analysts recently commented on ENZ shares. BidaskClub lowered Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Finally, TheStreet lowered Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.

COPYRIGHT VIOLATION NOTICE: “Evermore Global Advisors LLC Acquires 130,287 Shares of Enzo Biochem, Inc. (ENZ)” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/11/22/evermore-global-advisors-llc-acquires-130287-shares-of-enzo-biochem-inc-enz.html.

Shares of Enzo Biochem, Inc. (NYSE ENZ) traded up $0.20 during midday trading on Wednesday, reaching $9.49. The company had a trading volume of 132,800 shares, compared to its average volume of 211,763. Enzo Biochem, Inc. has a 52-week low of $6.27 and a 52-week high of $12.04.

In other Enzo Biochem news, CEO Elazar Rabbani sold 72,401 shares of the business’s stock in a transaction that occurred on Wednesday, October 25th. The stock was sold at an average price of $10.09, for a total value of $730,526.09. Following the completion of the transaction, the chief executive officer now directly owns 2,038,474 shares of the company’s stock, valued at $20,568,202.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP James Michael O’brien sold 22,866 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $10.28, for a total value of $235,062.48. Following the completion of the transaction, the executive vice president now directly owns 34,886 shares of the company’s stock, valued at $358,628.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 191,398 shares of company stock worth $1,925,292. 9.50% of the stock is owned by insiders.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.